Indications Listed in Dosage. Dosage PO Osteoarthritis 60 mg once daily. Rheumatoid arthritis 90 mg once daily.

Acute gout 120 mg once daily. Max duration: 8 days. Click to view etoricoxib Dosage by Indications Administration May be taken with or without food. Contraindications Inflammatory bowel disease, severe congestive heart failure, active peptic ulceration, cerebrovascular disease, CrCL <30 ml/min; lactation. Children and adolescent < 16 yr. Special Precautions Allergic disorders, coagulation defects; history of cardiac failure, left ventricular dysfunction, hypertension, or in patients with oedema due to other reasons; elderly, renal, cardiac or hepatic impairment. Withdraw treatment if GI lesions develop; caution when admin to dehydrated patients. Regular BP monitoring is advisable. May mask fever and other signs of infection. Pregnancy. Adverse Drug Reactions GI disorders; ischemic cardiac events; hypersensitivity reactions, headache, dizziness, nervousness, depression, drowsiness, insomnia, vertigo, tinnitus, photosensitivity; blood disorders, fluid retention, hypertension; dry mouth, taste disturbance, mouth ulcers; appetite and wt changes; chest pain, fatigue, paraesthesia, influenza-like syndrome, myalgia. Renal toxicity. Drug Interactions CYP3A4 inhibitors or inducers; rifampicin, ethinyloestradiol; oral salbutamol and minoxidil. Antidepressant SSRIs and venlafaxine may increase risk of bleeding. Risk of side effects increased with concomitant use of aspirin, ciclosporin, ketorolac or other NSAIDs. Lithium and methotrexate, coumarins, phenindione, phenytoin and sulphonylureas. Mechanism of Action For details of the mechanism of action, pharmacology and pharmacokinetics and toxicology ... click to view etoricoxib MIMS Class Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) ATC Classification M01AH05 - Etoricoxib ; Belongs to the class of non-steroidal antiinflammatory and antirheumatic products, coxibs.

convulsions (overdosage). Drug Interactions Enhances activity of oral anticoagulants but rarely significant. Increases risk of GI irritation with alcohol. Increased ciclosporin, lithium toxicity and convulsions reported with ciprofloxacin. Absorption increased by magnesium hydroxide antacids. ACE inhibitor effects may be antagonised. Lab Interference For caution against possible drug interference in lab test results ... click to view mefenamic acid Pregnancy Category (US FDA) Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.

in 3rd trimester or near delivery. Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). Mechanism of Action For details of the mechanism of action, pharmacology and pharmacokinetics and toxicology ... click to view mefenamic acid MIMS Class Nonsteroidal AntiInflammatory Drugs (NSAIDs) ATC Classification M01AG01 - Mefenamic acid ; Belongs to the class of non-steroidal antiinflammatory and antirheumatic products, fenamates.

ndications Pain and inflammation. Dosage PO 250500 mg 3 times/day. Click to view mefenamic acid Dosage by Indications Administration Should be taken with food. Contraindications Inflammatory bowel disease; peptic ulcer; neonates; pregnancy (3rd trimester), lactation. Coronary artery bypass graft surgery, severe renal impairment, severe heart failure. Special Precautions Renal and hepatic impairment, asthma. Monitor blood counts and liver function during longterm therapy. Drowsiness may affect ability to perform skilled tasks. Elderly. Adverse Drug Reactions Abdominal pain, dyspepsia, constipation, diarrhoea, nausea, GI ulcers; oedema; bronchospasm; headache, drowsiness, insomnia, visual disturbances; CHF, hypertension, tachycardia, syncope; urticaria, rash; thrombocytopenia, aplastic anaemia, agranulocytosis; tinnitus; elevated liver enzymes; abnormal renal function. Potentially Fatal: Autoimmune haemolytic anaemia;